Clinical Trials Logo

Colorectal Cancer Recurrent clinical trials

View clinical trials related to Colorectal Cancer Recurrent.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06314971 Recruiting - Colorectal Cancer Clinical Trials

Predicting Local and Distant Recurrence in T1 Colorectal Cancer

T1CR
Start date: March 15, 2023
Phase:
Study type: Observational

Tumor recurrence significantly affects survival rates following the local resection of submucosal colorectal cancers (T1 CRC). Despite this, there are currently no reliable biomarkers established to predict recurrence in T1 CRC. This study seeks to improve the prediction of recurrence-free survival in individuals who have survived T1 CRC.

NCT ID: NCT06314958 Recruiting - Colorectal Cancer Clinical Trials

Stage II/III Colorectal Cancer Recurrence

CENSURE
Start date: March 15, 2023
Phase:
Study type: Observational

This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.

NCT ID: NCT06229340 Recruiting - Lung Cancer Clinical Trials

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

N??-RAS
Start date: October 3, 2023
Phase: Phase 2
Study type: Interventional

There is a huge variety of nucleotide substitutions that activate RAS. The search for new "universal" drugs for the RAS pathway that either interfere with RAS upregulation upstream in the signaling pathway or offset the consequences of RAS activation is important for improving therapeutic outcomes for patients with refractory malignancies. The use of leflunomide or the combination of MEK inhibitor + hydroxychloroquine ± bevacizumab is promising for patients with mutations in RAS cascade genes who have failed all existing treatment standards.

NCT ID: NCT04067986 Recruiting - Clinical trials for Colorectal Cancer Recurrent

Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer

Start date: August 20, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The efficacy and safety of the use of Camrelizumab combined with Apatinib